Paper Details

  1. Home
  2. Paper Details

Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.

Author: ItonagaIchiro, IwasakiTatsuya, KakuNobuhiro, KawanoMasanori, KubotaYuta, TanakaKazuhiro, TsumuraHiroshi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This case report describes a patient with NTRK fusion-positive sarcoma who achieved disease control for over 21 months with sequential treatment using larotrectinib after progression on entrectinib. This suggests that sequential treatment may be effective in certain cases.
Paper Details　
Original Abstract of the Article :
Precision medicine and tumor-agnostic treatment strategies have recently been promoted for clinical use. One of the most successful treatments in patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors is targeting the tropomyosin receptor kinase (TRK) with an inhibitor. Th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10713097/

データ提供：米国国立医学図書館（NLM）

Sequential TRK Inhibitor Therapy: A New Oasis in the Desert of NTRK Fusion-Positive Sarcoma

In the vast and often-treacherous desert of cancer treatment, precision medicine has emerged as a beacon of hope, offering targeted therapies that specifically attack cancer cells. This case report focuses on the use of TRK inhibitors, a class of drugs that target the neurotrophic tyrosine receptor kinase (NTRK), in a patient with NTRK fusion-positive sarcoma. The researchers describe the patient's treatment journey, exploring the effectiveness of sequential therapy with two different TRK inhibitors, larotrectinib and entrectinib.

Navigating the Desert of NTRK Fusion-Positive Sarcoma

The case report illustrates the potential for sequential TRK inhibitor therapy to provide sustained disease control in patients with NTRK fusion-positive tumors. While entrectinib initially proved effective, the patient's tumor eventually progressed. However, switching to larotrectinib led to a remarkable response, with the patient achieving disease control for over 21 months.

An Oasis of Personalized Treatment

This case report offers a valuable glimpse into the potential of personalized treatment strategies for patients with NTRK fusion-positive tumors. The findings highlight the importance of tailoring treatment plans based on individual patient responses and the potential for sequential therapy to overcome resistance to initial treatments.

Dr. Camel's Conclusion

This case report provides a compelling example of the potential benefits of sequential TRK inhibitor therapy in patients with NTRK fusion-positive sarcoma, highlighting the importance of personalized treatment strategies and the ongoing need for research to optimize the use of targeted therapies in cancer treatment.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-12-08
Further Info :

Pubmed ID

38065851

DOI: Digital Object Identifier

PMC10713097

Related Literature

Article Analysis
・Effects of larotrectinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.